← Back to Calendar

Protagonist Therapeutics Q1 2026 Earnings

Protagonist Therapeutics · $PTGX

Standard Review Earnings

PDUFA Date

May 8, 2026

Time Remaining

45 days

Review Type

Standard (10 mo)

Indication

Q1 2026 earnings + rusfertide REVIVE Phase 3 data update

Key Notes

Q1 2026 earnings call expected ~May 8, 2026. Key update on rusfertide REVIVE Phase 3 trial in polycythemia vera — topline data expected H2 2026. Will confirm or adjust timeline.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar